147 related articles for article (PubMed ID: 24074769)
1. Personalizing extent of breast cancer surgery according to molecular subtypes.
Morrow M
Breast; 2013 Aug; 22 Suppl 2():S106-9. PubMed ID: 24074769
[TBL] [Abstract][Full Text] [Related]
2. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
3. Outcome in breast molecular subtypes according to nodal status and surgical procedures.
Mazouni C; Rimareix F; Mathieu MC; Uzan C; Bourgier C; André F; Delaloge S; Garbay JR
Am J Surg; 2013 Jun; 205(6):662-7. PubMed ID: 23312273
[TBL] [Abstract][Full Text] [Related]
4. Is conservative surgery a good option for patients with "triple negative" breast cancer?
Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
6. Presenting features of breast cancer differ by molecular subtype.
Wiechmann L; Sampson M; Stempel M; Jacks LM; Patil SM; King T; Morrow M
Ann Surg Oncol; 2009 Oct; 16(10):2705-10. PubMed ID: 19593632
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
9. Who should not undergo breast conservation?
Nijenhuis MV; Rutgers EJ
Breast; 2013 Aug; 22 Suppl 2():S110-4. PubMed ID: 24074770
[TBL] [Abstract][Full Text] [Related]
10. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results: double lumpectomies for multicentric breast carcinoma.
Kapoor NS; Chung A; Huynh K; Giuliano AE
Am Surg; 2012 Dec; 78(12):1345-8. PubMed ID: 23265123
[TBL] [Abstract][Full Text] [Related]
13. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
14. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
15. Locoregional recurrence in patients with triple-negative breast cancer: preliminary results of a single institution study.
Dragun AE; Pan J; Rai SN; Kruse B; Jain D
Am J Clin Oncol; 2011 Jun; 34(3):231-7. PubMed ID: 20805742
[TBL] [Abstract][Full Text] [Related]
16. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of triple negative in stage II/III breast cancer.
Elnashar AT; Ali el-SM; Gaber A
J Oncol Pharm Pract; 2012 Mar; 18(1):68-75. PubMed ID: 21422149
[TBL] [Abstract][Full Text] [Related]
18. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
Parker CC; Ampil F; Burton G; Li BD; Chu QD
Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
[TBL] [Abstract][Full Text] [Related]
20. Close/positive margins after breast-conserving therapy: additional resection or no resection?
Wood WC
Breast; 2013 Aug; 22 Suppl 2():S115-7. PubMed ID: 24074771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
